We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Apatinib for hepatocellular carcinoma.
- Authors
Ni, Yang; Ye, Xin
- Abstract
Primary hepatocellular carcinoma (HCC) ranks the second leading cause of cancer-related deaths in men worldwide with a poor prognosis.[[1]] For advanced patients, sorafenib is currently the standard therapy, which extended the overall survival (OS) by 2.8 months compared to best supportive care.[[2]] However, high cost, drug resistance, and severe side effects often lead to treatment discontinuation.[[3]] Apatinib (Hengrui Pharmaceutical Co., Ltd, Shanghai, China) is a novel, small-molecule, tyrosine kinase inhibitor which has higher selective inhibition of vascular endothelial growth factor receptor-2 than sorafenib, leading to suppression of tumor growth by targeting tumor angiogenesis. Furthermore, 6- and 12-month OS rates were 73.8% and 55.4%, respectively.[[6]] In another recently reported retrospective study, 25 patients with unresectable or relapsed HCC were treated with apatinib until progressive disease or unacceptable toxicity. In a single-center, randomized controlled trial, a total of 44 patients with moderate or advanced HCC were randomly assigned with transcatheter arterial chemoembolization (TACE) alone or combined treatment of TACE with apatinib.
- Subjects
HEPATOCELLULAR carcinoma; HEAD &; neck cancer; ANTINEOPLASTIC agents; LIVER tumors; PYRIDINE; TREATMENT effectiveness; CHEMOEMBOLIZATION
- Publication
Journal of Cancer Research & Therapeutics, 2019, Vol 15, Issue 4, p741
- ISSN
0973-1482
- Publication type
editorial
- DOI
10.4103/jcrt.JCRT_400_19